The six working groups covering the full spectrum of psychedelic research have been established with leaders from across Europe. Each group brings together specialists from multiple disciplines to address key challenges in psychedelic science.
The Six Working Groups
WG1 — Chemistry & Biophysics
Focused on the development of new molecules and formulations, analytical chemistry, and biophysical characterization of psychedelic compounds for therapeutic applications.
WG2 — Preclinical Research
Dedicated to understanding the underlying neurobiology from the molecular level, developing robust animal models, and establishing preclinical efficacy and safety profiles.
WG3 — Clinical
Responsible for designing and coordinating multicentre academic clinical trials, developing standardized treatment protocols, and establishing best practices for psychedelic-assisted therapy.
WG4 — Advances in NeuroImaging
Leveraging cutting-edge neuroimaging techniques to understand the neural mechanisms underlying psychedelic effects on consciousness and mental health.
WG5 — Data Sharing & Databases
Creating open access data platforms, standardizing data collection across studies, and enabling big data analysis to accelerate research discoveries.
WG6 — Policy Making
Addressing outdated regulatory frameworks, working with regulatory authorities on reclassification of psychedelics, and advocating for evidence-based policy changes at the EU and UN level.
